DB06001ExperimentalSmall molecule
DA-967b is an investigational antiplatelet agent that inhibits collagen and ristocetin-mediated platelet activation.
- Primary indication
- Investigated for use/treatment in thrombosis.Curator reviewed
- Code names
- DZ-697b
What you can answer from here — as of March 06, 2025
Which companies are running trials of DA-697b, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account